Miscellaneous treatments for neuroleptic-induced tardive dyskinesia (Q24248650)

Europe PubMed Central

title

Miscellaneous treatments for neuroleptic-induced tardive dyskinesia (English)

1 reference

Cochrane Database of Systematic Reviews

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

1

0 references

author name string

Claire B Irving

series ordinal

2

0 references

John Rathbone

series ordinal

3

0 references

publication date

22 April 2003

0 references

published in

0 references

different from

Miscellaneous treatments for neuroleptic-induced tardive dyskinesia.

0 references

Miscellaneous treatments for neuroleptic-induced tardive dyskinesia

0 references

cites work

Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Estrogen replacement and tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Treatment of tardive dyskinesia with ceruletide: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Low doses of insulin as a treatment of tardive dyskinesia: conjuncture or conjecture?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Naloxone in tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Tardive dyskinesia: A clinical test of the supersensitivity hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

High-dose naloxone in tardive dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Naloxone and naltrexone in mental illness and tardive dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Naltrexone treatment of tardive dyskinesia in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Benzodiazepines for neuroleptic-induced tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Clinical implications of Brief Psychiatric Rating Scale scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

What does the PANSS mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

A rating scale for tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Calcium channel blockers for neuroleptic-induced tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Cholinergic medication for neuroleptic-induced tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Cognitive rehabilitation for people with schizophrenia and related conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Deanol, lithium and placebo in the treatment of tardive dyskinesia. A double-blind crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Effect of lithium on neuroleptic-induced tardive dyskinesia compared with placebo in a double-blind cross-over trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Lithium carbonate in the treatment of tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Lithium in tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Failure of lithium treatment in established tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

The effect of ceruletide on tardive dyskinesia: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Tardive Dyskinesia Exacerbated after Ingestion of Phenylalanine by Schizophrenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Essential fatty acid supplementation in tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Enkephalin, morphine, and naloxone in tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Effect of des-tyrosine-gamma-endorphin in tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

The effects of electromyographic feedback training on suppression of the oral-lingual movements associated with tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Vasopressin in anergic schizophrenia. A cross-over study with lysine-8-vasopressin and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Serotonin precursor effects in tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Changes in tardive dyskinesia symptoms in elderly patients treated with ganglioside GM1 or placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Letter: Fenfluramine and dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Naloxone, tardive dyskinesia, and endogenous beta-endorphin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Estrogens in Tardive Dyskinesia in Male Psychiatric Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Lithium and lecithin in tardive dyskinesia: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Deanol in tardive dyskinesia: a double-blind study (author's transl)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Estrogen treatment of dyskinetic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Diabetes and development of tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

Anticholinergic medication for neuroleptic-induced tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

7 January 2021

Vitamin E for neuroleptic-induced tardive dyskinesia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

7 January 2021

Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

7 January 2021

Treatment of drug-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000208

7 January 2021